2cureX strengthen its patent portfolio with the granting of a new European patent
2cureX AB (“2cureX”) is pleased to announce the grant of European patent No. 3164709 “Identifying compounds modifying a cellular phenotype”. The patent protects the use of patient-derived micro-tumors for cancer treatment design. Together with 2cureX’s existing patent portfolio the patent provides a broad protection of the company’s IndiTreat technology in its European launch markets. The patent is valid until July 2035. The patent is currently also being prosecuted in territories outside Europe (e.g. USA).The IndiTreat technology generates thousands of small micro-tumors (tumoroids) from a